Electroporation Instruments - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The electroporation instruments market size is expected to grow from USD 453.70 million in 2025 to USD 504 million in 2026 and is forecast to reach USD 857.5 million by 2031 at 11.19% CAGR over 2026-2031. This report is Segmented by Instrument (Total Electroporation System, and More), Application (Protein Production, and More), End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, and More), Mode (In Vitro/Ex Vivo, in Vivo), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Electroporation Instruments Market Trends and Insights

Shift to Non-Viral Delivery for CGT and Gene Editing

Transposon-mediated gene integration eliminates the immunogenicity and insertional-mutagenesis concerns associated with lentiviral or adeno-associated viral vectors, making electroporation central to the transition toward scalable allogeneic CAR-T platforms. Closed-system flow electroporators now process up to 200 billion cells per batch, a throughput unattainable with legacy cuvette designs. ISO 13485-certified devices accelerate notified-body reviews and facilitate cross-reference of Device Master Files in investigational new drug (IND) applications, compressing chemistry-manufacturing-controls (CMC) timelines by 4-6 months. The growing availability of Master Files at the FDA further tilts sponsor preference toward electroporation, as validation data can be leveraged across programs . Collectively, these factors lift procurement budgets among vertically integrated biopharma firms and CDMOs alike.

Expansion of Electrochemotherapy and IRE in Clinical Oncology

Late-2024 FDA clearance for the NanoKnife system expanded irreversible electroporation beyond investigational use, offering prostate-cancer patients nerve-sparing treatment with 84% disease-free status at 12 months . Scandinavian ChemoTech secured an Indian import license in March 2026, unlocking a large price-sensitive oncology pool and highlighting the modality’s accessibility in resource-constrained settings. Ongoing randomized trials in Denmark may reduce bleomycin doses by 50%, lowering chemotherapy costs per cycle. Veterinary oncology provides a parallel revenue stream: more than 3,000 treatments have been completed globally, validating safety and efficacy in large animals and reducing translational risk to human indications. Regulatory pathways under the FDA’s 510(k) process and adaptive European frameworks shorten time-to-market for new indications.

Cell Viability and Cytotoxicity Constraints at Scale

Electroporation triggers caspase-mediated apoptosis in modified cells when voltage gradients exceed 1,200 V/cm or pulse durations surpass 10 ms. Every percentage point of viability lost translates into dose yield reductions, a critical issue for allogeneic CAR-T batches exceeding 200 billion cells. Mechanical transfection alternatives post 92% viability but lack industrial throughput capacity. Process tweaks - lower buffer ionic strength, chilled cuvettes, extended recovery - can recover 5-8 percentage points yet necessitate full GMP revalidation, adding half a year to technology-transfer schedules. Capital-intensive retrofits with impedance sensors remain limited to roughly one-third of the installed base, prolonging exposure to yield variability risk.

Other drivers and restraints analyzed in the detailed report include:

• High-Throughput and Automated Electroporation Platforms in GMP
• In Vivo DNA/RNA Vaccine Delivery and Immunotherapy Use-Cases
• Strong Competition from LNPs and Viral Vectors for In Vivo Delivery

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The electroporation instruments market for gene and cell therapy manufacturing accounted for 34.89% of 2025 revenue and is projected to expand at a 11.9% CAGR between 2026 and 2031. Transition from autologous to allogeneic workflows demands reproducible, high-throughput transfection conditions, uniquely met by flow-electroporation systems that handle 200-billion-cell batches without open handling steps. Automated electroporation integrated in single-use, closed cartridges lowers labor input and reduces contamination risk, helping CDMOs meet tighter release timelines written into milestone-based clinical supply contracts. Electrochemotherapy for cutaneous lesions and irreversible electroporation for solid tumors represent mature niches that contribute long-tail consumable sales, with India’s 2026 regulatory clearance for IQwave exemplifying cost-conscious emerging-market traction.

Secondary applications, such as transient protein production, benefit from stable titers above 3 g/L using transposon-enabled electroporation, enabling bioreactor runs beyond 60 generations. In vivo DNA and RNA vaccine delivery remains small in revenue terms yet strategically significant; a potential INO-3107 approval would de-risk broader oncology and infectious-disease pipelines. Biomedical research continues to provide steady, albeit lower-margin, instrument demand; however, commodity cuvettes from Asian suppliers are compressing prices by roughly 12% relative to 2023 levels, prompting established brands to migrate laboratories toward GMP-ready upgrades.

Biotechnology and pharmaceutical companies retained the largest 42.89% revenue share in 2025, reflecting in-house GMP builds aimed at safeguarding proprietary cell-engineering protocols. Yet CDMOs are set to post the fastest 12.6% CAGR through 2031 as sponsors pivot to asset-light development strategies that defer capital expenditure until late-phase trials. Japanese, Indian, and Chinese service providers have announced multi-billion-cell capacity expansions that combine automated electroporation with viral-vector production under single-contract umbrellas, reducing technology-transfer friction for global clients.

Hospitals and specialty clinics represent a smaller, high-growth channel, fueled by the adoption of electrochemotherapy and irreversible electroporation systems for nerve-sparing oncology procedures, reimbursed under new Current Procedural Terminology (CPT) codes. Academic and research institutes have lengthened upgrade cycles to 8-10 years, tempering short-term unit sales but furnishing a conversion pipeline for GMP-compliant replacements.

Complete Report Scope:

• By Instrument
  • Total Electroporation System
  • Eukaryotic Electroporation System
  • Microbial Electroporation System
• By Application
  • Protein Production
  • Gene Therapy / Cell Therapy Manufacturing
  • Electrochemotherapy (ECT)
  • Irreversible Electroporation (IRE)
  • In Vivo DNA/RNA Vaccine & Gene Delivery
  • Biomedical Research (Academic/Industrial)
• By End User
  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutes
  • CROs & CDMOs
  • Hospitals & Specialty Clinics
• By Mode
  • In Vitro / Ex Vivo
  • In Vivo
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 38.19% of global revenue in 2025, buoyed by National Institutes of Health grants for non-viral delivery platforms and by clear CBER guidance on Device Master Files. Distribution agreements that place electroporation instruments alongside established reagent catalogs have widened the sales reach into academic labs, enabling upgrades to GMP-compliant systems. Clarity around reimbursement for irreversible electroporation has underpinned a rapid increase in NanoKnife placements in U.S. urology suites.

Europe’s growth remains dampened by Medical Device Regulation (MDR) bottlenecks that double conformity-assessment timelines and push some suppliers to prioritize North American launches. Notified-body capacity constraints have extended approval cycles to 24-30 months, favoring incumbents with dedicated regulatory teams and encouraging consolidation among smaller vendors. Despite these hurdles, irreversible electroporation studies in Denmark and Germany continue to broaden the European evidence base, positioning ECT and IRE devices for accelerated uptake once certificates are secured.

Asia-Pacific is forecast to outpace all other regions at an 11.93% CAGR through 2031 as Japan, China, and India commission automated GMP suites that embed electroporation at mass scale. Teijin’s Iwakuni upgrade to more than 1,000 CAR-T lots per year illustrates Japan’s leadership in flow-based closed systems. India’s first domestically produced CAR-T approvals de-risk local capacity investments, with CDMOs targeting sub-USD 60,000 price points suited to the country’s payer mix. China’s Porton Advanced already runs 200-billion-cell batches, demonstrating readiness for late-phase global trials. South Korea and Brazil represent nascent opportunities contingent on clearer reimbursement pathways and local GMP infrastructure build-outs.

List of Companies Covered in this Report:

• AngioDynamics
• BEX Co., Ltd.
• BioEra Life Sciences
• Bio-Rad Laboratories
• Celetrix
• Eppendorf
• Etta Biotech
• Harvard Bioscience (BTX)
• Ichor Medical Systems
• IGEA S.p.A.
• Inovio Pharmaceuticals, Inc
• Leroy Biotech
• Lonza Group
• MaxCyte
• Mirai Medical
• Mirus Bio (EZporator)
• Nepa Gene
• OncoSec Medical
• Scandinavian ChemoTech
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support